Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma

SIM0505, an ADC candidates Simcere Zaiming developed using proprietary technology platform, is entering trials both in China and the USA

COSELA and Enlituo, two of Simcere Zaiming’ innovative product included in National Medical Insurance Catalogue

China NMPA approves Simcere’s Sanbexin^® sublingual tablets for the treatment of Acute Ischemic Stroke

First Patient Enrolled in Phase III Clinical Trial of Deunoxavir Marboxil (An Innovative Anti-Influenza Drug) for Pediatric Indication

Simcere Zaiming’s Pol θ inhibitor obtained IND approval from US FDA

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United Stated Food and Drug Administration

Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor

Simcere Zaiming’s novel molecule targeting the synthetic lethal pathway Pol θ has obtained approval for clinical trials in China

New Drug Application for Novel Anti-Insomnia Drug Quviviq^® Accepted